CREDIT AGREEMENT Dated as of September 18, 2018 amongCredit Agreement • September 21st, 2018 • Cancer Genetics, Inc • Services-medical laboratories • Delaware
This Credit Agreement (as it may be amended, restated, supplemented, or modified and in effect from time to time, this “Agreement”), dated as of September 18, 2018 is entered into by and between Cancer Genetics, Inc., a Delaware corporation (together with its successors and permitted assigns, “Borrower”) and NovellusDX, Ltd., a company established under the laws of the State of Israel (“Lender”).
AGREEMENT AND PLAN OF MERGER Among CANCER GENETICS, INC. WOGOLOS LTD. AND NOVELLUSDX LTD. Dated as of September 18, 2018Agreement and Plan of Merger • September 21st, 2018 • Cancer Genetics, Inc • Services-medical laboratories • Delaware
AGREEMENT AND PLAN OF MERGER, dated as of September 18, 2018 (this “Agreement”), among CANCER GENETICS, INC., a Delaware corporation (“CGI”), WOGOLOS LTD., a company formed under the laws of the State of Israel (“Merger Sub”) and registered under No. 51-588480-7 with the Israeli Registrar of Companies, and NOVELLUSDX LTD., a company formed under the laws of the State of Israel (“NDX”) and registered under No. 514625391 with the Israeli Registrar of Companies.
CANCER GENETICS, INC. SHAREHOLDER VOTING AGREEMENTShareholder Voting Agreement • September 21st, 2018 • Cancer Genetics, Inc • Services-medical laboratories • Delaware
THIS VOTING AGREEMENT (“Agreement”), dated as of September 18, 2018, is made by and among NOVELLUSDX LTD., a company formed under the laws of the State of Israel (“NDX”) and the undersigned holder (“CGI Shareholder”) of the number and class set out Schedule 1 of shares (the “CGI Shares”) and/or options (“CGI Options”) and/or warrants (“CGI Warrants”) of CANCER GENETICS, INC., a Delaware corporation (“CGI”).
NOVELLUSDX SHAREHOLDER VOTING AGREEMENTNovellusdx Shareholder Voting Agreement • September 21st, 2018 • Cancer Genetics, Inc • Services-medical laboratories • Delaware
THIS VOTING AGREEMENT (“Agreement”), dated as of September 18, 2018, is made by and among CANCER GENETICS, INC., a Delaware corporation (“CGI”), and the undersigned holder (“NDX Shareholder”) of the number and class set out Schedule 1 of shares (the “NDX Shares”) and/or options (“NDX Options”) and/or warrants (“NDX Warrants”) of NOVELLUSDX LTD., a company formed under the laws of the State of Israel and registered under No. 514625391 with the Israeli Registrar of Companies (“NDX”).
